GREENLAND MINES LTD financials

GRML CIK 0001907223

Source: EDGAR filings · Built 2026-06-19T02:27:23Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2022
Working Capital 7.22M -1.09M -1.61M -66.08K -3.56K
Net Debt 177.01K 1.31M
Return on Equity (ROE) -111.50% -518.87% 159.80% -30.49% 100.00%
Return on Assets (ROA) -109.99% -250.28% -32.26% 1.04% -71.87%
Current Ratio 95.01× 0.13× 0.00× 0.87× 0.58×
Debt-to-Equity 0.20× -2.96×
Effective Tax Rate -97.61% 20.70%
Cash Conversion Ratio 0.56× 0.48× 0.63× -0.40× -1.39×
Accruals Ratio -0.49× -1.30× -0.12× 0.01× -1.72×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2022
Research and Development Expense 634.19K 0 0
Operating Expenses 7.15M 5.54M 631.32K
Operating Income (Loss) -7.15M -5.54M -631.32K -657.02K -3.56K
Income Tax Expense (Benefit) 690.57K 322.02K
Net Income (Loss) Attributable to Parent -10.55M -6.15M -707.46K 1.23M -3.56K
Earnings Per Share, Basic $-0.22 $-0.32 $-0.05
Weighted Average Number of Shares Outstanding, Basic 48.49M 19.25M 15.13M
Earnings Per Share, Diluted $-0.22 $-0.32 $-0.05
Weighted Average Number of Shares Outstanding, Diluted 48.49M 19.25M 15.13M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2022
Cash and Cash Equivalents, at Carrying Value 7.18M 63.74K 2.81K 340.96K
Assets, Current 7.29M 157.81K 6.65K 440.16K 4.95K
Assets 9.59M 2.46M 2.19M 118.25M 4.95K
Liabilities, Current 76.76K 1.25M 1.62M 506.24K 8.51K
Liabilities 129.76K 1.27M 1.62M 4.93M 8.51K
Stockholders' Equity Attributable to Parent 9.46M 1.19M -442.70K -4.04M -3.56K
Common Stock, Shares, Outstanding 72.54M 27.08M 15.13M 3.40M 0

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2022
Net Cash Provided by (Used in) Operating Activities -5.89M -2.95M -446.92K -493.04K 4.95K
Net Cash Provided by (Used in) Investing Activities -123.50K 23.85K -116.15M
Net Cash Provided by (Used in) Financing Activities 13.00M 3.13M 350.00K 116.98M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (GRML CIK 0001907223), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

JSPRW

JASPER THERAPEUTICS, INC.

SMFNF

SUMITOMO MITSUI FINANCIAL GROUP, INC.

BTAI

BioXcel Therapeutics, Inc.